Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
TRINITY is designed as a multicentre, randomized, open-label, interventional phase II study aimed at investigating the activity, efficacy and safety of trastuzumab-deruxtecan (T-DXd) plus capecitabine/5-fluorouracil as a post-operative treatment in localized/locally advanced gastric or gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma patients with HER2 overexpression/amplification and positive post-operative ctDNA after pre-operative 5-fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) regimen followed by radical surgery.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Generalny stan zdrowia pozwalający na leczenie (ECOG 0-1)
- •Spodziewana długość życia co najmniej 12 tygodni
- •Usunięty chirurgicznie rak żołądka lub połączenia przołyku ze żołądkiem po chemioterapii przedoperacyjnej
- •Brak przerzutów w innych częściach ciała potwierdzone badaniami obrazowymi
- •Nowotwór ma określoną cechę HER2 potwierdzoną w tkance operacyjnej
- •Ślady raka wykryte w krwi 2-6 tygodni po operacji
- •Dobra funkcja serca, szpiku i wątroby potwierdzona badaniami laboratoryjnymi
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Milan, Italy
Trial contact
Filippo Pietrantonio, MD
Federica Palermo
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.